These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7564482)

  • 1. Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol.
    Pabst R; Delventhal S; Gebert A; Hensel A; Petzoldt K
    Lung; 1995; 173(4):233-41. PubMed ID: 7564482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses.
    Katinger A; Lubitz W; Szostak MP; Stadler M; Klein R; Indra A; Huter V; Hensel A
    J Biotechnol; 1999 Aug; 73(2-3):251-60. PubMed ID: 10486934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization by the enteral and respiratory route with viable and inactivated bacteria results in a differential increase in lymphocyte subsets in the bronchoalveolar space.
    Pabst R; Delventhal S; Hensel A; Petzoldt K
    Adv Exp Med Biol; 1995; 371B():1459-61. PubMed ID: 7502837
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral immunization with lung-pathogenic bacteria is protective against defined challenge in a pig aerosol infection model.
    Hensel A; Delventhal S; Windt H; Stockhofe-Zurwieden N; Pabst R; Petzoldt K
    Adv Exp Med Biol; 1995; 371B():803-6. PubMed ID: 7502901
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge.
    Hensel A; Stockhofe-Zurwieden N; Petzoldt K; Lubitz W
    Infect Immun; 1995 Aug; 63(8):3048-53. PubMed ID: 7622229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge.
    Hensel A; Stockhofe-Zurwieden N; Ganter M; Petzoldt K
    Vet Microbiol; 1995 Nov; 47(1-2):27-41. PubMed ID: 8604553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular changes in the bronchoalveolar lavage (BAL) of pigs, following immunization by the enteral or respiratory route.
    Delventhal S; Hensel A; Petzoldt K; Pabst R
    Clin Exp Immunol; 1992 Nov; 90(2):223-7. PubMed ID: 1424278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood lymphocyte subsets in pigs vaccinated and challenged with Actinobacillus pleuropneumoniae.
    Appleyard GD; Furesz SE; Wilkie BN
    Vet Immunol Immunopathol; 2002 Jul; 86(3-4):221-8. PubMed ID: 12007888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity following immunisation of pigs with aerosol of Actinobacillus pleuropneumoniae serotype 2.
    Loftager MK; Eriksen L; Aasted B; Nielsen R
    Res Vet Sci; 1993 Nov; 55(3):281-6. PubMed ID: 8284489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.
    Hensel A; Huter V; Katinger A; Raza P; Strnistschie C; Roesler U; Brand E; Lubitz W
    Vaccine; 2000 Jul; 18(26):2945-55. PubMed ID: 10825595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and aerosol immunization with viable or inactivated Actinobacillus pleuropneumoniae bacteria: antibody response to capsular polysaccharides in bronchoalveolar lavage fluids (BALF) and sera of pigs.
    Hensel A; Pabst R; Bunka S; Petzoldt K
    Clin Exp Immunol; 1994 Apr; 96(1):91-7. PubMed ID: 8149673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model.
    Hensel A; van Leengoed LA; Szostak M; Windt H; Weissenböck H; Stockhofe-Zurwieden N; Katinger A; Stadler M; Ganter M; Bunka S; Pabst R; Lubitz W
    J Biotechnol; 1996 Jan; 44(1-3):171-81. PubMed ID: 8717401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosol treatment of pigs with Actinobacillus pleuropneumoniae serotype 2: mucosal immunity and resistance against challenge.
    Loftager MK; Eriksen L; Nielsen R
    Adv Exp Med Biol; 1995; 371B():1611-4. PubMed ID: 7502867
    [No Abstract]   [Full Text] [Related]  

  • 14. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
    Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
    Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Actinobacillus pleuropneumoniae infection in piglets with different types and levels of specific protection: immunophenotypic analysis of lymphocyte subsets in the circulation and respiratory mucosal lymphoid tissue.
    Faldyna M; Nechvatalova K; Sinkora J; Knotigova P; Leva L; Krejci J; Toman M
    Vet Immunol Immunopathol; 2005 Aug; 107(1-2):143-52. PubMed ID: 15963572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction.
    Goethe R; Gonzáles OF; Lindner T; Gerlach GF
    Vaccine; 2000 Nov; 19(7-8):966-75. PubMed ID: 11115723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs.
    Furesz SE; Mallard BA; Bossé JT; Rosendal S; Wilkie BN; MacInnes JI
    Infect Immun; 1997 Feb; 65(2):358-65. PubMed ID: 9009283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge.
    Yuan F; Liao Y; You W; Liu Z; Tan Y; Zheng C; BinWang ; Zhou D; Tian Y; Bei W
    Vet Microbiol; 2014 Dec; 174(3-4):531-539. PubMed ID: 25465668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.